Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors

Publisher Website
Google Scholar
Abstract
Vinblastine sulfate, 0.10–0.15 mg/kg IV every week, was given to 37 patients with bidimensionally measurable, metastatic transitional cell carcinoma of the urothelial tract. Twenty-eight patients, the majority of whom had received extensive prior chemotherapy, had an adequate trial and five (18%; 95% confidence limits, 3–33%) achieved a partial remission (>50% decrease in tumor size) of 2–5 months' duration. Responding sites included lung and nodal metastases. Toxicity, primarily leukopenia, was mild to moderate. The 18% response rate obtained in heavily pretreated cases suggests that vinblastine sulfate has some efficacy in the treatment of patients with advanced urothelial tract tumors.